Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020067399 - ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION

Publication Number WO/2020/067399
Publication Date 02.04.2020
International Application No. PCT/JP2019/038087
International Filing Date 27.09.2019
IPC
C07K 16/46 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C12N 15/09 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
C12P 21/08 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
08Monoclonal antibodies
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
Applicants
  • CHUGAI SEIYAKU KABUSHIKI KAISHA [JP]/[JP]
Inventors
  • IGAWA, Tomoyuki
  • FENG, Shu
  • HO, Shu Wen Samantha
  • SHIRAIWA, Hirotake
Agents
  • HARUNA, Masao
  • SHIMIZU, Hatsushi
  • YAMAGUCHI, Hirotaka
  • OSAKABE, Suguru
  • INOUE, Ryuichi
  • SATO, Toshimitsu
  • SHIMMI, Hirokazu
  • KOBAYASHI, Tomohiko
  • KODERA, Hideki
  • OHZEKI, Masato
  • IGARASHI, Yoshihiro
  • KAWAMOTO, Kazuya
Priority Data
2018-18512028.09.2018JP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION
(FR) MOLÉCULE DE LIAISON À L'ANTIGÈNE COMPRENANT UNE RÉGION VARIABLE D'ANTICORPS MODIFIÉE
Abstract
(EN)
An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and/or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen-binding molecule is capable of modulating and/or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug.
(FR)
La présente invention concerne une molécule de liaison à l'antigène capable de se lier à de multiples antigènes différents (par exemple, CD3 sur des lymphocytes T, et CD137 sur des lymphocytes T, des cellules NK, des cellules DC, et/ou analogues), mais ne réticulent pas de manière spécifique deux cellules immunitaires ou plus telles que des lymphocytes T. La molécule de liaison à l'antigène multispécifique, selon la présente invention est capable de moduler et/ou d'activer une réponse immunitaire tout en contournant la réticulation entre différentes cellules (par exemple, différents lymphocytes T) résultant de la liaison d'une molécule de liaison à l'antigène multispécifique classique à des antigènes exprimés sur différentes cellules, qui est considérée comme responsable des réactions indésirables lorsque la molécule de liaison à l'antigène multispécifique est utilisée en tant que médicament.
Latest bibliographic data on file with the International Bureau